Evolus, Inc. (NASDAQ:EOLS) CFO Sells $119,286.96 in Stock

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 8,996 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $119,286.96. Following the completion of the transaction, the chief financial officer now directly owns 173,583 shares in the company, valued at $2,301,710.58. This represents a 4.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sandra Beaver also recently made the following trade(s):

• On Monday, December 23rd, Sandra Beaver sold 1,586 shares of Evolus stock. The stock was sold at an average price of $10.85, for a total transaction of $17,208.10.

Evolus Trading Down 1.6 %

Shares of Evolus stock opened at $13.25 on Friday. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The stock has a market capitalization of $842.53 million, a P/E ratio of -14.56 and a beta of 1.28. Evolus, Inc. has a 52-week low of $9.25 and a 52-week high of $17.82. The stock’s 50-day simple moving average is $13.36 and its 200 day simple moving average is $13.91.

Institutional Trading of Evolus

A number of institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Evolus by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,451 shares of the company’s stock worth $347,000 after acquiring an additional 1,094 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Evolus by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock valued at $148,000 after purchasing an additional 1,291 shares during the last quarter. Rhumbline Advisers grew its stake in Evolus by 2.2% in the 4th quarter. Rhumbline Advisers now owns 80,149 shares of the company’s stock worth $885,000 after buying an additional 1,762 shares in the last quarter. Tradition Wealth Management LLC increased its holdings in shares of Evolus by 18.2% in the 4th quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company’s stock worth $144,000 after buying an additional 2,000 shares during the last quarter. Finally, MetLife Investment Management LLC raised its position in shares of Evolus by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 34,272 shares of the company’s stock valued at $378,000 after buying an additional 2,044 shares in the last quarter. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Barclays increased their price target on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Evolus in a research note on Wednesday, March 5th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.